ESMO 2021

European Society for Medical Oncology 2021

The annual ESMO Congress will feature the latest advances in cancer treatment through an educational program led by various delegates from all around the world.

 

Boehringer Ingelheim is dedicated to collaborating with the oncology community on a shared journey to deliver innovative treatments for patients with cancer. At the congress we will be presenting findings regarding new treatment options for multiple tumor types. More information is provided below.

 

11 publications
Virtual format
Thursday 16 September – Tuesday 21 September 2021
Virtual format
Publications

Explore our latest clinical data during the scientific program at ESMO.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumor Type
  • All tumor types
Thursday, 16 September – Tuesday, 21 September 2021
A Phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: a snapshot analysis
Author(s): Johnson et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: 524
Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours
Author(s): Girard et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: 532
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours
Author(s): Hussein et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: 541
Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours
Author(s): Patel et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: 542
Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
Author(s): Kotecki et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: 983
A Phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma
Author(s): Gounder et al.
Poster Presentation
Tumor Type(s): sarcoma
Presentation Number: 1548
Afatinib for the treatment of NSCLC with uncommon EGFR mutations: an updated database of 1023 cases
Author(s): Yang et al.
Poster Presentation
Tumor Type(s): non-small cell lung cancer
Presentation Number: 1212
EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: a real-world cohort study (UpSwinG)
Author(s): Miura et al.
Poster Presentation
Tumor Type(s): non-small cell lung cancer
Presentation Number: 1217
Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: a non-interventional cohort study (UpSwinG)
Author(s): Popat et al.
Poster Presentation
Tumor Type(s): non-small cell lung cancer
Presentation Number: 1223
Elderly patients treated with afatinib in clinical practice – final results of the GIDEON study in EGFR mutated NSCLC in Germany
Author(s): Brueckl et al.
Poster Presentation
Tumor Type(s): non-small cell lung cancer
Presentation Number: 1230
Second-line nintedanib + docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: updated efficacy and safety results from VARGADO Cohort C
Author(s): Grohé et al.
Poster Presentation
Tumor Type(s): lung adenocarcinoma
Presentation Number: 1569
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

Pipeline compounds shown here are under preclinical and/or clinical investigation, and have not been approved. Their safety and efficacy have not been established.

 

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here . Registration conditions differ internationally; please refer to locally approved prescribing information.

 

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

 

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: September 2021